Yahoo Finance

Operations: NCC Group plc generates revenue primarily from Cyber Security (£258.50 million) and Escode (£65.90 million). The company operates across multiple regions including the UK, Asia-Pacific, North America, and Europe.

NCC Group, recently added to the FTSE 250 and FTSE 350 indices, demonstrates a promising trajectory despite current unprofitability. With an expected revenue growth of 4.5% per year—surpassing the UK market average of 3.8%—and a projected earnings increase of 87.4%, NCC is poised for significant financial recovery. This growth is underpinned by strategic expansions like the SEK 450 million water infrastructure project in Sweden, enhancing municipal services and environmental compliance. Moreover, with R&D expenses strategically allocated to foster innovation and efficiency within its cybersecurity solutions, NCC aligns well with industry demands for enhanced digital security measures, setting a robust foundation for future profitability and market competitiveness.

• Dive into the specifics of NCC Group here with our thorough health report.

• Evaluate NCC Group's historical performance by accessing our past performance report.

Oxford Biomedica

Simply Wall St Growth Rating: ★★★★★☆

Overview: Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide and has a market cap of £401.88 million.

Operations: Oxford Biomedica generates revenue primarily through its Platform segment, which contributed £97.24 million. The company operates as a contract development and manufacturing organization, focusing on delivering therapies globally.

Oxford Biomedica, despite its current unprofitability, is on a robust upward trajectory with revenue forecasted to grow at 21% annually, significantly outpacing the UK market average of 3.8%. This growth is bolstered by a substantial projected increase in earnings of 106.13% per year over the next three years. The company's commitment to R&D is evident as it strategically channels funds into this area, ensuring innovation remains at the forefront of its operations amid evolving biotech landscapes. Recent executive changes and reaffirmed financial guidance further underscore Oxford Biomedica's proactive approach in strengthening its market position and enhancing shareholder value through focused leadership and clear strategic directives.

• Get an in-depth perspective on Oxford Biomedica's performance by reading our health report here.

• Learn about Oxford Biomedica's historical performance.

Taking Advantage

• Embark on your investment journey to our 47 UK High Growth Tech and AI Stocks selection here.

• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.

• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LSE:GNS LSE:NCC and LSE:OXB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com